Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

JAZZ

+ Watchlist+ Portfolio

Jazz Pharmaceuticals plc

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$240.71
52-Week Range
$156.95 – $266.38
Market Cap
$15.90B
P/E (TTM)
73.30
EPS (TTM)
3.38
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.79
PEG Ratio
0.96
Return on Equity
5.05%
Return on Assets
6.92%
Gross Margin
91.10%
Operating Margin
27.39%
Profit Margin
4.36%
Current Ratio
1.82
Debt/Equity
1.35
Total Debt
$5.65B
Free Cash Flow
$1.68B
Revenue Growth
10.40%
Earnings Growth
—
Enterprise Value
$18.69B

Market Snapshot

About

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases with significant unmet medical needs, particularly in neuroscience and oncology. The company is best known for Xyrem and Xywav, treatments for narcolepsy and idiopathic hypersomnia, which generate substantial revenue. Jazz markets Epidiolex for seizures associated with rare forms of epilepsy and Zepzelca for small cell lung cancer. The company maintains a robust pipeline of late-stage development programs and pursues strategic acquisitions to expand its portfolio.